Skip to main content


Rosenberg and VanCamp

One Lab, One Discovery: The Continuous Ripple Effect

Posted: Tuesday, October 26, 2021
Category: Foundation News

Nearly six decades after cisplatin’s founding, the anti-cancer drug’s legacy resonates across the MSU landscape. Through the MSU Foundation, some $325 million in cisplatin and carboplatin royalties earned from 1979-2004 have pushed MSU investigators to pursue daring work, fueled enterprising interdisciplinary explorations and propelled countless entrepreneurial adventures.  

“Cisplatin wasn’t just a home run,” current MSU Foundation Executive Director David Washburn said. “It was a grand slam.”

Read more at…

About the Michigan State University Foundation

Established in 1973 as an independent non-profit, the Michigan State University Foundation is committed to the commercialization of cutting-edge technologies invented by MSU faculty, staff, and students. The MSU Foundation’s overarching goal is to support research, innovation, and entrepreneurship at the University. Additionally, the MSU Foundation operates Spartan Innovations, Red Cedar Ventures, Michigan Rise, and the University Corporate Research Park. More information on the organization’s notable achievements, services, leadership, and history are available at